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Abstract
Massive pulmonary embolism (PE), characterised by profound arterial hypotension, is a life-threatening emergency with a 
90-day mortality of over 50%. Systemic thrombolysis can significantly reduce the risk of death or cardiovascular collapse 
in these patients, by around 50%, but these benefits are offset by a fivefold increased risk of intracranial haemorrhage and 
major bleeding, which may limit its use in patients at high risk of catastrophic haemorrhage. We describe a case series of 
3 patients presenting with massive PE, each with extreme risk of bleeding and contra-indication to systemic thrombolysis, 
treated successfully with ultrasound-assisted, catheter directed thrombolysis (U-ACDT). Our experience of this novel tech-
nique using the EkoSonic Endovascular System (Ekos, BTG, London, UK) on carefully selected patients has demonstrated 
the potential to improve clinical status in shocked patients, with minimal bleed risk. There have been several clinical studies 
evaluating the Ekos system. Both the ULTIMA and SEATTLE II studies have shown significant reductions in RV/LV ratio 
by CT scanning when compared to standard anticoagulation in patients with intermediate-risk PE, with minimal bleeding 
complications. However, there is a pressing need for a randomised trial demonstrating improvement in robust clinical out-
comes when comparing U-ACDT to simple anticoagulation. We believe that this case series adds new insight and highlights 
the potential of catheter directed thrombolysis in this high-risk patient cohort and consideration should be made to its use 
in cases where systemic thrombolysis is felt to be too high risk.
Keywords Massive Pulmonary Embolism · Thrombolysis · Catheter directed thrombolysis · Interventional cardiology · 
Bleed risk
Highlights
• Management of multi-comorbid patients with life-threat-
ening massive PE is complex, and competent multidisci-
plinary PERT input in decision-making is vital.
• These cases have shown the potential of U-ACDT in 
patients with massive PE and extreme bleed risk with 
good outcomes.
• Further comprehensive, prospective and randomised 
evaluation is required in both patients with submassive, 
and massive PE.
Summary
Massive pulmonary embolism (PE), characterised by 
profound arterial hypotension, is a life-threatening emer-
gency with a 90-day mortality of over 50% [1]. Systemic 
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thrombolysis can significantly reduce the risk of death or 
cardiovascular collapse in these patients, by around 50%, 
but these benefits are offset by a fivefold increased risk 
of intracranial haemorrhage and major bleeding, which 
may limit its use in patients at high risk of catastrophic 
haemorrhage [1–3].
Subsequently, advanced novel technologies have been 
developed with lower bleed risk. We describe the effective 
co-ordination of our multidisciplinary pulmonary embo-
lism response team (PERT) and successful treatment of 
three patients with massive PE and extreme bleeding risk 
with ultrasound-assisted, catheter directed thrombolysis 
(U-ACDT).
Methods
The EkoSonic Endovascular System (BTG, London, United 
Kingdom) uses a catheter to deliver thrombolytic directly 
to pulmonary arteries. Ultrasound emitters emit high fre-
quency, low power ultrasound, intended to disaggregate 
fibrin fibres and thereby improve drug delivery, allowing 
use of a fraction of the systemic fibrinolytic dose [4].
Patients were selected based on clinical need at a single 
institution (Royal Devon & Exeter Hospital, Exeter, UK) 
without on-site cardiothoracic surgery, having had a con-
firmed diagnosis with CT pulmonary angiography (CTPA) 
and a physiological assessment with echocardiography. Each 
case was discussed by multidisciplinary team (comprising 
cardiology, respiratory, intensive care, and interventional 
radiology) and the need for emergency treatment confirmed, 
along with the contraindications to systemic thrombolysis. 
Subsequently, cases were discussed with our institution’s 
medical director or his immediate deputy to approve use.
All patients were transferred to the cardiac catheter labo-
ratory at our institution, with haemodynamic monitoring 
throughout. Under aseptic conditions, two 6F sheaths were 
inserted with the use of a 4F micro-puncture needle under 
direct ultrasound guidance into the right femoral vein. A 
long 0.035 guidewire and multipurpose catheter were used 
to traverse the right heart into the pulmonary arteries. An 
ultrasound catheter was exchanged over the wire and inserted 
into the left, right, or both pulmonary arteries (depending on 
thrombus burden). Alteplase was infused at a rate of 1 mg/
catheter/h along with saline coolant at 35 mL/h, with a fixed 
infusion of unfractionated heparin (500 iu/h) into a periph-
eral vein. Echocardiography was performed immediately 
post procedure, at 6 h, and again the following day.
Patient 1
A 73-year-old lady was admitted with abrupt circulatory col-
lapse, with an arterial blood pressure of 55/35 mmHg 7 days 
after undergoing retro-mastoid craniectomy and excision of 
a solitary cerebellar metastasis (Fig. 1a pre, 1b post-surgery) 
secondary to treatment-responsive adenocarcinoma of the 
lung. Her ECG showed widespread, non-specific T-wave 
changes and bedside echocardiography demonstrated severe 
right heart dilatation and impairment, with septal flattening 
(Fig. 1c).
Emergency CTPA, performed using gadolinium due to a 
history of anaphylaxis to iodinated contrast, confirmed the 
diagnosis of massive PE with bilateral proximal thrombus 
(Fig. 1d). Her pulmonary embolism severity index (PESI) 
was calculated at 273 [5].
After MDT discussion, where systemic thrombolysis was 
felt to be too high risk of intra-cranial haemorrhage, she 
was transferred to the cardiac catheter lab, requiring intra-
venous adrenaline both en route and repeatedly during the 
case for profound hypotension. U-ACDT was performed 
to both pulmonary arteries. At five hours, following 9 mg 
of alteplase, normal haemodynamic parameters had been 
restored. She returned to the rehabilitation ward at 48 h, and 
was discharged home 8 days later, at Cerebral Performance 
Category 1 [6], with persistence of post-operative diplopia, 
but no new neurological impairment.
Patient 2
A 70-year-old hypertensive female presented with syncope 
following 2 days of dyspnoea, chest pain and pre-syncope, 
on a background of 1 week of right iliac fossa pain. She was 
transported via air ambulance and on arrival in the emer-
gency department was hypotensive, with a blood pressure 
of 90/50 mmHg, and hypoxic, with peripheral saturations 
of 83% on air.
A point of care haemoglobin was measured at 70 g/L. 
She underwent urgent CTPA, with coverage extended 
to include the abdomen given her clinical history. This 
demonstrated extensive bilateral PE (Fig. 2a) with right 
heart dilatation and marked caecal thickening, suggestive 
of malignancy, with localised bowel perforation (Fig. 2b).
Bedside echocardiography confirmed severe right heart 
dilatation and impairment, with pulmonary hypertension 
(RV:LV 1.8, estimated pulmonary artery systolic pres-
sure (PASP = 50 mmHg, severe tricuspid regurgitation—
Fig. 2c). Her high-sensitivity troponin T was elevated at 
seven times the normal upper limit.
She was commenced on broad spectrum antibiotics and 
reviewed by the PERT team. It was clear she was unlikely 
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to survive without early bowel surgery, which could not 
take place given her haemodynamic instability. Systemic 
thrombolysis was felt to be too high risk for intra-abdom-
inal haemorrhage.
She therefore underwent U-ACDT in the cardiac cath-
eter laboratory, using a total of 9 mg alteplase over 4.5 h 
without any exacerbation of her chronic gastrointestinal 
haemorrhage. The following day, her blood pressure had 
improved to 135/75 mmHg. There was improvement in her 
right ventricular and right atrial dimensions, reduction in 
the PASP and improvement in the tricuspid regurgitation 
(Fig. 2d).
Two weeks later she underwent a right hemicolectomy, 
with excision of a large caecal tumour involving the ovary 
and small bowel mesentery. After 36 h on the intensive care 
unit (ICU), she was returned to the ward, and was discharged 
home 8 days later.
Patient 3
A 33-year-old woman admitted for an elective Caesarean 
section for her second pregnancy suffered a cardiac arrest 
shortly after anaesthetic induction. The baby was success-
fully delivered, and cardiopulmonary resuscitation achieved 
return of spontaneous circulation. She was transferred to 
the ICU where she became haemodynamically unstable. 
She was taken back to theatre where ongoing bleeding was 
identified, and an emergency hysterectomy was performed.
On return to ICU, she suffered a further cardiac arrest. 
Emergency transthoracic echocardiography demonstrated 
a dilated and impaired right heart and a large right atrial 
thrombus (Fig. 3a). Given her major abdominal surgery and 
bleeding risk, she was initially managed conservatively with 
intravenous heparin, requiring intermittent vasopressor sup-
port. Repeat echocardiography at 3 h showed the absence 
of right atrium thrombus, presumably due to embolisation.
Fig. 1  a Right sided solitary 
cerebellar metastasis pre, and b 
post-surgery, c Echocardiogram 
showing dilated right ventricle, 
d CTPA with gadolinium con-
trast showing bilateral PE
 J. He et al.
1 3
On day 1 post-surgery, she became increasingly unsta-
ble, with progressive hypotension, rising lactate and coag-
ulopathy (INR 2.8, APTR 2.0, fibrinogen undetectable) 
and thrombocytopenia. CTPA showed a saddle PE with 
heavy clot burden particularly in the left pulmonary artery 
(Fig. 3b), dilated right heart and a RV:LV ratio of 1.2. On 
day 2, following multi-disciplinary review, and with increas-
ing inotrope requirements, a decision was made to attempt 
U-ACT.
In the cardiac catheter laboratory, a single ultrasound 
catheter was inserted into the left pulmonary artery (Fig. 3c). 
A total of 14 mg of alteplase was infused over 24 h through 
the device. During this time, she experienced no bleeding 
complications. At the end of the procedure all inotropic sup-
port was able to be withdrawn and her PASP was 19 mmHg.
Repeat CTPA 3 days later showed a significantly reduced 
clot burden in the left pulmonary artery with a reduction in 
size of the right ventricle (Fig. 3d). She was extubated on 
day 5, mobilising around the ward on day 8 and discharged 
on day 10. At 1 year, both patient and baby are well, and the 
patient’s echocardiogram demonstrates normal right ventric-
ular size, function and estimated pulmonary artery pressures.
Discussion
Venous thromboembolism (VTE) is the third most common 
cardiovascular disease, with an annual incidence of between 
75 and 269 cases per 100 000 [5]. Most cases (60%) are low 
risk and managed with oral anticoagulation with a low risk 
of death (approx. 2%). This increases to 30% in the presence 
of shock and as high as 70% if cardiac arrest occurs [6]. In 
patients with massive PE with haemodynamic collapse and 
shock, full-dose systemic thrombolysis is required as a salvage 
intervention.
In these critically unwell patients, the importance of timely 
formulation of effective treatment by specialist is vital. This is 
reflected by the emergence of multidisciplinary rapid-response 
teams for the treatment of intermediate/high risk PE. The set-
up of PERT is encouraged by the latest 2019 ESC and Euro-
pean Respiratory Society PE guidelines [7].
Conventional lysis
The use of systemic thrombolysis is associated with a signif-
icant reduction in mortality—approximately half compared 
Fig. 2  a CTPA showing bilat-
eral PE, b CT abdomen showing 
marked caecal thickening (red 
arrow) and adjacent air pocket 
secondary to bowel perforation 
(blue arrow), c and d degree of 
TR pre, and post U-ACD
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to anticoagulation alone, even with intermediate risk PE, but 
associated with a significant risk of major bleeding [2, 3, 8].
It is therefore unsurprising that most contraindications 
to thrombolysis are related to bleeding risk. The American 
Heart Association (AHA) and European Society of Cardiol-
ogy (ESC) guidelines are similar, with absolute contraindi-
cations including known malignant intracranial neoplasm or 
recent surgery (within 3 weeks) encroaching on the spinal 
canal or brain, and patients with active (or at high risk of) 
bleeding [9, 10]. The ESC also considers gastrointestinal 
bleeding within 4 weeks an absolute contraindication, and 
pregnancy as a relative contraindication. However, the ESC 
guideline concludes that “most contraindications to throm-
bolysis should be considered relative in patients with life-
threatening, high-risk PE.”[9].
Unfortunately, the aetiology of PE often includes 
contraindication(s) to its treatment. Malignancy is a well-
recognised risk factor for the development of pulmonary 
emboli, conferring a relative risk of up to 7 times that of the 
general population, with brain tumours associated with par-
ticularly high risk [11, 12]. Pregnancy is another high-risk 
state, with a sixfold incidence in PE [13]. The development 
of PE is also more likely in patients who are convalescing 
due to intercurrent illness, which may also preclude conven-
tional thrombolysis. Age is also highly relevant, with those 
over the age of 65 at greatest risk from lytic therapy [2, 8].
Catheter‑based techniques
Historically, there have been limited high quality, large scale 
studies assessing outcomes of catheter-based embolectomy, 
with data derived from registries and pooled results, and 
with case series suggesting procedural success rates of 87% 
[14]. However, these studies may be subject to selection 
and publication bias. More recently, there have been several 
cohort studies and one RCT.
Although early studies were disappointing, the limitations 
of conventional therapy encouraged development of novel 
alternative treatments [15]. These approaches generally uti-
lise local or directed thrombolysis intended to reduce throm-
bolytic dose, and mechanical thrombus disruption, including 
Fig. 3  a Transthoracic echocar-
diogram from the subcostal 
view showing large RA throm-
bus, b CTPA showing bilateral 
PE, c EKOS catheter in left 
PA, d repeat CTPA 3 days later 
showing reduced clot burden in 
left PA
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aspiration. Some techniques employ both. These methods 
remain in early clinical assessment.
The Ekos system uses ultrasound arrays within a sheath to 
deliver alteplase via acoustic streaming directly into the clot, 
thereby increasing the surface area of thrombus subject to 
contact with tPA. This may reduce the amount of thrombo-
lytic required [16, 17]. Its use has been evaluated in several 
clinical studies.
The ULTIMA trial compared U-ACDT with intravenous 
heparin to intravenous heparin alone in 59 intermediate-risk 
patients, demonstrating improved RV/LV ratio at 24 h with 
U-ACDT and no significant difference in mortality or major 
bleeding at 90 days [18].
The SEATTLE II study also showed improved mean 
RV/LV ratio 48 h post procedure (1.55 vs 1.13; p < 0.0001) 
along with a reduction in mean PASP (51.4 mmHg vs. 
36.9 mmHg; p < 0.0001) in 150 patients with acute mas-
sive, or submassive PE with no incidence of intracranial 
haemorrhage [19].
More recently, the OPTALYSE study was conducted on 
101 haemodynamically stable patients with submassive PE, 
with four different treatment dose/duration protocols [20]. 
This showed a similar improvement in RV/LV ratio with 
each protocol, although there was a dose/duration-of-treat-
ment relationship with thrombus burden reduction. There 
were two episodes of serious bleeding in the highest dose 
protocol (24 mg alteplase over 6 h), which was discontinued.
These three studies report on six different treatment pro-
tocols to use. It is currently unclear what the most appropri-
ate dose/duration is, and it unlikely to be a “one size fits all” 
treatment, with protocol selection being patient dependent 
(clinical status, comorbidity, thrombus burden, bleed risk).
Conclusion
There is a pressing need for high quality randomised con-
trol trials demonstrating improvement in robust clinical out-
comes when comparing U-ACDT to simple anticoagulation 
in intermediate/high risk PE.
For massive PE, systemic thrombolysis can significantly 
reduce risk of death or cardiovascular collapse. However, 
these benefits are offset by a significant risk of bleeding, lim-
iting its use in patients at risk of catastrophic haemorrhage.
The occurrence of massive PE in patients at high risk 
of haemorrhagic complications is likely to increase as the 
global population ages, and patients live with multiple 
comorbidities. This case series highlights the potential 
of catheter-based thrombolysis in clinical scenarios that 
are becoming more commonplace. The ability to achieve 
thrombus dissolution in the 3 patients discussed here proved 
lifesaving, and the application of U-ACDT in this high-risk 
group warrants comprehensive, prospective, and randomised 
evaluation.
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